Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Cochlear Limited    COH   AU000000COH5

End-of-day quote. End-of-day quote  - 09/26
139.07 AUD   -0.66%
09/15 COCHLEAR : Broader Insurance Coverage for Cochlear Implants Announce..
09/14 COCHLEAR : Voting Form
09/14 COCHLEAR : Notice of Annual General Meeting
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cochlear Limited : COH Jury Trial Verdict on USA Patent Infringement Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2014 | 03:51am CEST
ASX RELEASE 24th January 2014 COCHLEAR LIMITED: JURY TRIAL VERDICT ON USA PATENT INFRINGEMENT CASE

Cochlear Limited, Sydney, 24th January 2014 (ASX:COH) today announced that a jury verdict in the patent infringement lawsuit by the Alfred E. Mann Foundation for Scientific Research ("AMF") and Advanced Bionics LLC ("AB") has been reached.
A jury in the United States District Court in Los Angeles, California found direct, contributory and wilful, but not induced infringement against Cochlear Limited and its USA subsidiary Cochlear Americas and awarded damages of US$131.2 million against Cochlear.
No judgment has been entered based on the verdict as important issues still remain to be decided by the Judge. These decisions may negate some of the findings of the jury and could alter the damages awarded by the jury.
Cochlear believes the facts and the law do not support the jury's findings and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
This lawsuit was disclosed to ASX when it was filed in December 2007. The verdict relates to two (2) United States patents on testing systems and methods for a cochlear implant. The patents were exclusively licenced by AMF to AB which is a competitor to Cochlear.
One of the patents expired in September 2009 and the other expires in March 2014. As a result, the verdict and any following judgment entered against Cochlear will not disrupt Cochlear's business or customers in the United States.
As at the date of this announcement, Cochlear had not accrued any liability in its financial statements for this verdict. In addition, Cochlear has not yet determined the impact, if any, on its financial statements.
Cochlear's Chief Executive Officer and President Dr Chris Roberts said, "We strongly disagree with the jury verdict and will appeal any judgment entered against Cochlear by the Court".
Ends
Company contacts:
Dr Chris Roberts, CEO/President p: + 61 2 9428 6555
Neville Mitchell, CFO
p: + 61 2 9428 6555

Page 1 of 1

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COCHLEAR LIMITED
09/17 COCHLEAR : MILITARY $50,500 Federal Contract Awarded to Cochlear Americas
09/15 COCHLEAR : Broader Insurance Coverage for Cochlear Implants Announced
09/14 COCHLEAR : Voting Form
09/14 COCHLEAR : Notice of Annual General Meeting
09/13 COCHLEAR : Appendix 3Y - Chris Smith
09/09 COCHLEAR : Patent Issued for Hearing Prosthesis Electrode Array with Resiliently..
09/07 COCHLEAR : Cable-free Cochlear Implant Processor Provides Flexibility
09/07 COCHLEAR LIMITED : ex-dividend day for final dividend
09/02 COCHLEAR : launches first off-the-ear hearing device
09/01 COCHLEAR : Nucleus® cochlear implants now have access to 3.0T MRI
More news
Sector news : Medical Prosthetics
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 2nd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 3rd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- Update
09/16DJJ&J Nears Deal to buy Abbott's Eye-Surgery Equipment Unit
More sector news : Medical Prosthetics
News from SeekingAlpha
08/11 How Do I Manage A Favorite Holding That's Now Overvalued?
07/07 Smaller Medtechs In Charge Of Their Own Destiny
04/03 The Psychology Of Investing
03/14 EWA : Getting In Down Under
2015 Cochlear Should Do Well As Its Target Market Expands
Advertisement
Financials ( AUD)
Sales 2017 1 239 M
EBIT 2017 306 M
Net income 2017 220 M
Debt 2017 55,7 M
Yield 2017 1,92%
P/E ratio 2017 36,13
P/E ratio 2018 32,28
EV / Sales 2017 6,53x
EV / Sales 2018 5,95x
Capitalization 8 036 M
More Financials
Chart COCHLEAR LIMITED
Duration : Period :
Cochlear Limited Technical Analysis Chart | COH | AU000000COH5 | 4-Traders
Full-screen chart
Technical analysis trends COCHLEAR LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 123  AUD
Spread / Average Target -12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christopher M. Smith President, Chief Executive Officer & Director
Roderick Holliday-Smith Chairman
Dig Howitt Chief Operating Officer
Neville J. Mitchell Chief Financial Officer & Secretary
James F. Patrick Chief Scientist & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COCHLEAR LIMITED46.46%6 122
MEDTRONIC PLC14.03%121 210
STRYKER CORPORATION26.71%44 078
BECTON DICKINSON AND C..16.49%38 220
ESSILOR INTL.2.91%28 988
BAXTER INTERNATIONAL I..24.48%25 829
More Results